Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul;14(7):864-873.
doi: 10.1111/jdi.14015. Epub 2023 May 5.

Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies

Sanbao Chai  1 , Fengqi Liu  2 , Shuqing Yu  2 , Zhirong Yang  3 , Feng Sun  2
Affiliations
Meta-Analysis

Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies

Sanbao Chai et al. J Diabetes Investig. 2023 Jul.

Abstract

Aims/introduction: Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors, in patients with type 2 diabetes mellitus.

Materials and methods: PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin-based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta-analysis.

Results: Pooled results showed that the Mini-Mental State Examination score in incretin-based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39-2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.

Conclusions: Current evidence shows that incretin-based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.

Keywords: Cognitive function; Incretin-based therapy; Type 2 diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of studies considered for inclusion.
Figure 2
Figure 2
Association of incretin‐based therapies and cognitive function in patients with type 2 diabetes mellitus. CI, confidence interval; SD, standard deviation.
See this image and copyright information in PMC

References

    1. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018; 138: 271–281. - PubMed
    1. Jash K, Gondaliya P, Kirave P, et al. Cognitive dysfunction: a growing link between diabetes and Alzheimer's disease. Drug Dev Res 2020; 81: 144–164. - PubMed
    1. Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national populationbased cohort study. JAMA Psychiat 2015; 72: 612–619. - PMC - PubMed
    1. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 2018; 14: 591–604. - PMC - PubMed
    1. Freedman BI, Sink KM, Hugenschmidt CE, et al. Associations of early kidney disease with brain magnetic resonance imaging and cognitive function in African Americans with type 2 diabetes mellitus. Am J Kidney Dis 2017; 70: 627–637. - PMC - PubMed

MeSH terms

Substances